DE60234116D1 - Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems - Google Patents

Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems

Info

Publication number
DE60234116D1
DE60234116D1 DE60234116T DE60234116T DE60234116D1 DE 60234116 D1 DE60234116 D1 DE 60234116D1 DE 60234116 T DE60234116 T DE 60234116T DE 60234116 T DE60234116 T DE 60234116T DE 60234116 D1 DE60234116 D1 DE 60234116D1
Authority
DE
Germany
Prior art keywords
obesity
piperidine
disorders
treatment
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234116T
Other languages
English (en)
Inventor
Duane A Burnett
Wen-Lian Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE60234116D1 publication Critical patent/DE60234116D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DE60234116T 2001-11-26 2002-11-25 Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems Expired - Lifetime DE60234116D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33336701P 2001-11-26 2001-11-26
PCT/US2002/037956 WO2003045918A1 (en) 2001-11-26 2002-11-25 Piperidine-based mch antagonists for treatment of obesity and cns disorders

Publications (1)

Publication Number Publication Date
DE60234116D1 true DE60234116D1 (de) 2009-12-03

Family

ID=23302485

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234116T Expired - Lifetime DE60234116D1 (de) 2001-11-26 2002-11-25 Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems

Country Status (18)

Country Link
US (1) US6664273B2 (de)
EP (1) EP1448526B1 (de)
JP (2) JP2005510563A (de)
KR (1) KR20040058307A (de)
CN (1) CN1592739A (de)
AR (1) AR037429A1 (de)
AT (1) ATE446286T1 (de)
AU (1) AU2002350269B2 (de)
CA (1) CA2467857C (de)
DE (1) DE60234116D1 (de)
ES (1) ES2333415T3 (de)
HU (1) HUP0402404A3 (de)
IL (1) IL161717A0 (de)
MX (1) MXPA04004956A (de)
PE (1) PE20030809A1 (de)
TW (1) TW200301115A (de)
WO (1) WO2003045918A1 (de)
ZA (1) ZA200403784B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
US6809104B2 (en) * 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
KR20040012851A (ko) * 2001-05-22 2004-02-11 뉴로젠 코포레이션 멜라닌 농축성 호르몬 수용체 리간드: 치환된1-벤질-4-아릴 피페라진 유사체
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
JP2005532991A (ja) * 2002-01-10 2005-11-04 ニューロジェン・コーポレーション メラニン凝集ホルモン受容体リガンド：置換２−（４−ベンジル−ピペラジン−１−イルメチル）−及び２−（４−ベンジル−ジアゼパン−１−イルメチル）−１ｈ−ベンゾイミダゾールアナログ
PL376659A1 (pl) * 2002-11-06 2006-01-09 Tularik Inc. Skondensowane związki heterocykliczne
AU2003284402A1 (en) * 2002-11-15 2004-06-15 Yamanouchi Pharmaceutical Co., Ltd. Antagonist to melanin-concentrating hormone receptor
JPWO2004069798A1 (ja) * 2003-02-10 2006-05-25 萬有製薬株式会社 ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0310724D0 (en) * 2003-05-09 2003-06-11 Glaxo Group Ltd Chemical compounds
US7345042B2 (en) * 2003-06-30 2008-03-18 Schering Corporation MCH antagonists for the treatment of obesity
EP1506967B1 (de) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl Peptidase Inhibitoren.
AR045496A1 (es) * 2003-08-29 2005-11-02 Schering Corp Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
BRPI0415051A (pt) 2003-10-01 2006-11-28 Procter & Gamble compostos antagonistas do hormÈnio concentrador de melanina e suas composições farmacêuticas
CN102134229B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
EP1729772B8 (de) * 2004-03-24 2017-04-19 Merck Sharp & Dohme Corp. Heteroaryl-piperidin-glycin-transporterhemmer
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
US7361769B2 (en) * 2004-07-16 2008-04-22 Schering Corporation Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1817032A2 (de) * 2004-11-29 2007-08-15 Vertex Pharmaceuticals Incorporated Modulatoren muskarinischer rezeptoren
EP1828192B1 (de) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidylpeptidasehemmer
US7655644B2 (en) * 2004-12-21 2010-02-02 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as GlyT1 inhibitors
WO2006105035A2 (en) * 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
EA015169B1 (ru) 2005-09-14 2011-06-30 Такеда Фармасьютикал Компани Лимитед Применение ингибиторов дипептидилпептидазы
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
GEP20125701B (en) * 2006-09-13 2012-12-10 Takeda Pharmaceuticals Co Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
MX2009010854A (es) 2007-04-11 2010-01-28 Omeros Corp Composiciones y metodos para profilaxis y tratamiento de adicciones.
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US20170280749A1 (en) * 2011-06-09 2017-10-05 Requis Pharmaceuticals Antihistamines Combined with Dietary Supplements for Improved Health
KR200487142Y1 (ko) 2017-05-31 2018-08-10 주식회사 에이치에스씨 2차코일이 일체로 형성된 트랜스포머용 가이더
JP2023509310A (ja) * 2019-12-18 2023-03-08 クリネティックス ファーマシューティカルズ，インク． Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267843A (de) * 1960-08-03
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
AU5135998A (en) 1996-12-03 1998-06-29 Banyu Pharmaceutical Co., Ltd. Novel urea derivatives
US5953440A (en) 1997-12-02 1999-09-14 Sensar, Inc. Method of measuring the focus of close-up images of eyes
IL139913A0 (en) 1998-06-08 2002-02-10 Schering Corp Neuropeptide y5 receptor antagonists
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
CA2407149C (en) 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
EP1377293B1 (de) * 2001-04-12 2010-03-10 Pharmacopeia, LLC Arly und diaryl piperidinderivate verwendbar als mch-hemmer
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
ATE446286T1 (de) 2009-11-15
CA2467857A1 (en) 2003-06-05
PE20030809A1 (es) 2003-09-22
EP1448526A1 (de) 2004-08-25
HUP0402404A2 (hu) 2005-03-29
ZA200403784B (en) 2005-05-19
KR20040058307A (ko) 2004-07-03
US20030199549A1 (en) 2003-10-23
EP1448526B1 (de) 2009-10-21
CA2467857C (en) 2010-08-24
HUP0402404A3 (en) 2011-05-30
WO2003045918A8 (en) 2005-03-17
TW200301115A (en) 2003-07-01
AU2002350269B2 (en) 2006-05-18
JP2005510563A (ja) 2005-04-21
JP2009256390A (ja) 2009-11-05
CN1592739A (zh) 2005-03-09
IL161717A0 (en) 2004-09-27
MXPA04004956A (es) 2004-08-11
AU2002350269A1 (en) 2003-06-10
US6664273B2 (en) 2003-12-16
ES2333415T3 (es) 2010-02-22
AR037429A1 (es) 2004-11-10
WO2003045918A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
DE60234116D1 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
ATE302185T1 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
ATE297380T1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60238149D1 (de) Arylsulfonamid-Derivate zur Verwendung als CCR3-Antagonisten bei der Behandlung von inflammatorischen und immunologischen Erkrankungen
ATE447552T1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE327757T1 (de) Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
ATE420866T1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE318821T1 (de) Pyranoindazole und ihre verwendung in der glaukombehandlung
DE60223715D1 (de) Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
ATE362473T1 (de) 1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten
ATE422202T1 (de) Substituierte 4-(indazol-3-yl)phenole als liganden des oestrogenrezeptors und deren verwendung bei der behandlung von entzündlichen erkrankungen
ATE269078T1 (de) Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
DE60022867D1 (de) 1-Arenesulfonyl-2-Aryl-Pyrrolidin und Piperidin Derivative zur Behandlung von CNS-Erkrankungen
NO20031903L (no) Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
DE502004011551D1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
ATE303379T1 (de) 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
ATE367160T1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
ATE359783T1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
DE69915113D1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
ATE514431T1 (de) Allergie-vakzine-zusammensetzung, herstellungsverfahren dafür und ihre verwendung bei der behandlung von allergien
EE200300527A (et) 4-(fenüülpiperidiin-4-ülideenmetüül)bensamiidi derivaadid ja nende kasutamine valu, ärevuse või seedetrakti häirete raviks

Legal Events

Date Code Title Description
8364 No opposition during term of opposition